Germany: Data quality proves Bayer's Eylea blind spot in battle against Novartis' Lucentis
This article was originally published in Scrip
Executive Summary
These is no evidence that Bayer/Regeneron's Eylea (aflibercept) offers any benefits over Novartis' Lucentis for treating wet AMD, according to IQWiG, the body the conducts the preliminary scientific assessment for Germany's AMNOG health technology appraisals.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.